Key Takeaways ANI Pharmaceuticals' 2025 revenue jumped 43.8% to $883.4M, led by Rare Disease and Brands growth.ANIP's Cortrophin Gel surged ~76% to $347.8M, becoming its primary specialty growth driver.ANI Pharmaceuticals expects retina recovery in 2026 after a 2025 reset amid reimbursement challenges.ANI Pharmaceuticals (ANIP) is reshaping its growth profile as specialty therapies take a larger share of the mix. Fiscal 2025 results show accelerating momentum in Rare Disease and Brands, led by Purified Cort ...

Core Insights - Cardinal Health (CAH) is positioned for growth due to the expansion of its specialty portfolio, with strong fiscal second-quarter results driven by pharmaceutical distribution and specialty services [2] - The company has seen a 49.2% increase in shares over the past six months, outperforming the industry and the S&P 500 [3] - Cardinal Health has a market capitalization of $53.26 billion and projects a 15% growth over the next five years, with consistent earnings surpassing estimates [4] Upsides - Strong momentum in the Pharmaceutical and Specialty Solutions segment, with revenue rising 19% to $61 billion and segment profit increasing 29% in Q2 of fiscal 2026, driven by demand across various therapeutic areas [6][9] - Specialty revenues are expected to exceed $50 billion in fiscal 2026, highlighting the company's shift towards higher-margin specialty therapies [6][9] - Adjacent businesses, including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics, delivered 34% revenue growth and 52% profit growth, supported by structural healthcare trends [10] Profitability Improvements - The Global Medical Products and Distribution (GMPD) segment showed progress with profit rising from $18 million to $37 million year over year, reflecting operational restructuring and stronger demand for branded products [11] - Improved service levels and supply chain efficiency are expected to enhance profitability in the GMPD segment [11] Downsides - Profit growth in the Pharma segment is expected to moderate to mid-teens levels in the second half of fiscal 2026 due to difficult comparisons from onboarding new customers and prior acquisitions [12] - The GMPD segment faces external cost pressures from tariffs, which could impact profitability and recovery within the turnaround plan [13] - The core pharmaceutical distribution business operates with thin margins, making sustained earnings expansion reliant on specialty services and adjacent businesses [14] Estimate Trends - The Zacks Consensus Estimate for earnings per share (EPS) has improved by 2.7% to $10.31 for 2026, with projected revenues for Q3 at $62.42 billion, indicating a 13.7% year-over-year improvement [15]